A team of SMU biological scientists has confirmed that P-glycoprotein (P-gp) has the ability to remove from the brain a toxin that is associated with…
Chatbots hold promise for dementia patient or caregiver support, but are still in their infancy, finds a paper published in the Journal of Medical Internet…
The U.S. Food and Drug Administration (FDA) recently approved aducanumab, the first treatment that aims to slow the progression of Alzheimer’s disease. But approval of…
Alzheimer’s disease is predominant in elderly people, but the way age-related changes to lipid composition affect the regulation of biological processes is still not well…
In a highly anticipated announcement, the U.S. Food and Drug Administration on Monday, June 7, approved the first new drug for Alzheimer’s disease in nearly…
A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of Alzheimer’s disease—before any symptoms of…
A new therapy prompts immune defense cells to swallow misshapen proteins, amyloid beta plaques and tau tangles, whose buildup is known to kill nearby brain…
An experimental Alzheimer’s vaccine appears to safely clear abnormal tau protein from the brain, but it’s not yet clear whether the shot will be able…
Alzheimer’s disease is the most common form of dementia and is characterized by neurodegeneration in regions of the brain involved in memory and learning. Amyloid…
Like amyloid plaque, the genetic variant APOE4 has long been associated with Alzheimer’s disease, but still little is known about the role the gene plays…